Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer-Reference-Cited by-同舟云学术

Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer

Published:2010-03-13 Issue:2 Volume:121 Page:261-271
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Perez Edith A.,Patel Tejal,Moreno-Aspitia Alvaro

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-010-0824-0.pdf

Reference60 articles.

1. Brennan DJ, O’Brien SL, Fagan A et al (2005) Application of DNA microarray technology in determining breast cancer prognosis and therapeutic response. Expert Opin Biol Ther 5:1069–1083

2. Kaklamani V (2006) A genetic signature can predict prognosis and response to therapy in breast cancer: oncotype DX. Expert Rev Mol Diagn 6:803–809

3. Cleator S, Heller W, Coombes RC (2007) Triple-negative breast cancer: therapeutic options. Lancet Oncol 8:235–244

4. Altmann KH, Wartmann M, O’Reilly T (2000) Epothilones and related structures—a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta 1470:M79–M91

5. Lee FY, Borzilleri R, Fairchild CR et al (2001) BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 7:1429–1437

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synergizing Immunotherapy and Antibody–Drug Conjugates: New Horizons in Breast Cancer Therapy;Pharmaceutics;2024-08-29

2. Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer;npj Breast Cancer;2024-04-25

3. Challenges in HER2-low breast cancer identification, detection, and treatment;Translational Breast Cancer Research;2024-01

4. Research Progress of Ebomycin Antitumor Drugs in Breast Cancer;Hans Journal of Medicinal Chemistry;2024

5. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer;Future Oncology;2023-11